Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PTPRB | P23467 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8009914 | 0.92 | LMNA (0.45) | LMNASMN1; SMN2TSHRMAPK1 | |
| Diatrizoic Acid SCHEMBL7615048 | 0.86 | LMNA (0.67) | LMNASMN1; SMN2TSHRMAPK1HPGD | |
| Diatrizoic Acid SCHEMBL8508 | 0.86 | LMNA (0.67) | LMNASMN1; SMN2TSHRMAPK1HPGD | |
| SCHEMBL8060106 | 0.84 | LMNA (0.71) | LMNASMN1; SMN2 | |
| Diatrizoic Acid SCHEMBL30451079 | 0.84 | LMNA (0.65) | LMNASMN1; SMN2TSHRMAPK1HPGD | |
| Diatrizoic Acid SCHEMBL5960726 | 0.84 | LMNA (0.65) | LMNASMN1; SMN2TSHRMAPK1HPGD | |
| Diatrizoic Acid SCHEMBL1197801 | 0.84 | LMNA (0.65) | LMNASMN1; SMN2TSHRMAPK1HPGD | |
| Diatrizoic Acid SCHEMBL3974126 | 0.84 | LMNA (0.65) | LMNASMN1; SMN2TSHRMAPK1HPGD | |
| Diatrizoic Acid SCHEMBL8509 | 0.84 | LMNA (0.65) | LMNASMN1; SMN2TSHRMAPK1HPGD | |
| Diatrizoic Acid SCHEMBL6362397 | 0.84 | LMNA (0.65) | LMNASMN1; SMN2TSHRMAPK1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478276-A4 | NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE | IMARX THERAPEUTICS INC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20050019266-A1 | Novel targeted compositions for diagnostic and therapeutic use | UNGER EVAN C (US) | 2005-01-27 | — | — | US | disclosed |
| EP-1478276-A2 | NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE | Imarx Therapeutics, Inc. (US) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003061593-A2 | NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE | IMARX THERAPEUTICS, INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| US-6558665-B1 | Encapsulating particles with coatings that conform to size and shape of the particles | ARCH DEVELOPMENT CORPORATION | 2003-05-06 | — | — | US | disclosed |
| US-20020159951-A1 | Novel targeted compositions for diagnostic and therapeutic use | IMARX THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| EP-0686046-B1 | CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 2000-05-24 | — | — | EP | disclosed |
| EP-0619716-B1 | CONTRAST MEDIA | NYCOMED IMAGING AS (NO) | 1998-08-05 | — | — | EP | disclosed |
| US-5767299-A | Contrast agents | NYCOMED IMAGING AS (NO) | 1998-06-16 | — | — | US | disclosed |
| US-5733525-A | Method of EII using a water insoluble particulate agent | NYCOMED IMAGING AS (NO) | 1998-03-31 | — | — | US | disclosed |
| EP-0578765-A1 | DELIVERY OF X-RAY CONTRAST AGENTS USING RECEPTOR MEDIATED ENDOCYTOSIS | ADVANCED MAGNETICS INCORPORATED (US) | 1994-01-19 | — | — | EP | disclosed |
| EP-0414287-B1 | Particulate contrast media | NYCOMED IMAGING AS (NO) | 1994-01-19 | — | — | EP | disclosed |
| US-5242683-A | Gastrointestinal tract, side effect reduction | NYCOMED IMAGING AS (NO) | 1993-09-07 | — | — | US | disclosed |
| WO-1993012717-A2 | CONTRAST MEDIA | COCKBAIN, JULIAN, RODERICK, MICHAELSON (GB) | 1993-07-08 | — | — | WO | disclosed |
| WO-1992017216-A1 | DELIVERY OF X-RAY CONTRAST AGENTS USING RECEPTOR MEDIATED ENDOCYTOSIS | ADVANCED MAGNETICS, INC. (US) | 1992-10-15 | — | — | WO | disclosed |
| US-5141739-A | Delivery of x-ray contrast agents using receptor mediated endocytosis | ADVANCED MAGNETICS, INC. (US) | 1992-08-25 | — | — | US | disclosed |
| EP-0483278-A1 | PARTICULATE CONTRAST MEDIA | NYCOMED AS (NO) | 1992-05-06 | — | — | EP | disclosed |
| EP-0473729-A1 | CONTRAST MEDIA | NYCOMED AS (NO) | 1992-03-11 | — | — | EP | disclosed |
| WO-1991001147-A1 | PARTICULATE CONTRAST MEDIA | NYCOMED AS (NO) | 1991-02-07 | — | — | WO | disclosed |
| WO-1991001149-A1 | CONTRAST MEDIA | NYCOMED AS (NO) | 1991-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050019266-A1 | Novel targeted compositions for diagnostic and therapeutic use | TPX2, FABP1, TNNI3 | LMNA 876/4885SMN1; SMN2 1235/4885TSHR 3265/4885 |
| US-20020159951-A1 | Novel targeted compositions for diagnostic and therapeutic use | FABP3, SELPLG, ASGR1 | LMNA 589/4885SMN1; SMN2 4821/4885TSHR 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.